S. Ekpanyapong and K. R. Reddy, Infections in cirrhosis, Curr Treat Options Gastroenterol, vol.17, pp.254-70, 2019.

A. Pauwels, L. Meunier, G. Boivineau, T. Martin, I. Touze et al., Resistant bacterial infections in cirrhosis: a French observational prospective multicentre nationwide study (RESIST study), J Hepatol, vol.66, pp.131-133, 2017.

V. Arvaniti, D. 'amico, G. Fede, G. Manousou, P. Tsochatzis et al.,

, Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis, Gastroenterology, vol.139, pp.1246-1256, 2010.

J. Fernández and T. Gustot, Management of bacterial infections in cirrhosis, J Hepatol, vol.56, pp.1-12, 2012.

E. Strauss, The impact of bacterial infections on survival of patients with decompensated cirrhosis, Ann Hepatol, vol.13, pp.7-19, 2014.

B. Chinnock, H. Afarian, H. Minnigan, J. Butler, and G. W. Hendey, Physician clinical Impression does not rule out spontaneous bacterial peritonitis in patients undergoing emergency department paracentesis, Ann Emerg Med, vol.52, pp.268-73, 2008.

B. Chinnock, G. W. Hendey, H. Minnigan, J. Butler, and H. Afarian, Clinical impression and ascites appearance do not rule out bacterial peritonitis, J Emerg Med, vol.44, pp.903-912, 2013.

C. Da, A. P. Eranki, and . Procalcitonin, StatPearls [Internet, 2019.

R. Dong, B. Wan, S. Lin, M. Wang, J. Huang et al., Procalcitonin and liver disease: a literature review, J Clin Transl Hepatol, vol.7, pp.51-56, 2019.

A. Mousa, N. Elhammady, D. Elhelaly, R. Elzehery, R. Elbaz et al., Ascitic fluid calprotectin and serum procalcitonin as accurate diagnostic markers for spontaneous bacterial peritonitis, Gut Liver, vol.10, pp.624-655, 2016.

S. H. Hoeboer, P. J. Van-der-geest, D. Nieboer, and A. Groeneveld, The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis, Clin Microbiol Infect, vol.21, pp.474-81, 2015.

J. Fernández, J. Acevedo, M. Castro, O. Garcia, R. De-lope et al.,

, Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective 16 study, Hepatology, vol.55, pp.1551-61, 2012.

M. Merli, C. Lucidi, V. Giannelli, M. Giusto, O. Riggio et al., Cirrhotic patients are at risk for health care-associated bacterial infections, Clin Gastroenterol Hepatol, vol.8, pp.979-985, 2010.

D. P. Bota, M. Van-nuffelen, A. N. Zakariah, and J. Vincent, Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver, J Lab Clin Med, vol.146, pp.347-51, 2005.

Z. Zhan, D. Zhang, P. Hu, Z. Zhou, Y. Deng et al., Serum procalcitonin in cirrhotic patients with sepsis, Chin J Hepatol, vol.23, pp.428-460, 2015.

G. Pieri, B. Agarwal, and A. K. Burroughs, C-reactive protein and bacterial infection in cirrhosis, Ann Gastroenterol, vol.27, pp.113-133, 2014.

E. Villarreal, K. Vacacela, M. Gordon, C. Calabuig, R. Alonso et al., Usefulness of procalcitonin for diagnosing infection in critically ill patients with liver cirrhosis, Med Intensiva Engl Ed, vol.40, pp.84-93, 2016.

Y. Cekin, A. H. Cekin, A. Duman, U. Yilmaz, B. Yesil et al., The role of serum procalcitonin levels in predicting ascitic fluid infection in hospitalized cirrhotic and noncirrhotic patients, Int J Med Sci, vol.10, pp.1367-1374, 2013.

L. Simon, F. Gauvin, D. Amre, P. Saint-louis, and J. Lacroix, Serum procalcitonin and Creactive protein levels as markers of bacterial infection: a systematic review and metaanalysis, Clinical Infectious Diseases, vol.39, pp.206-217, 2004.

S. Connert, W. Stremmel, and C. Elsing, Procalcitonin is a valid marker of infection in decompensated cirrhosis, Zeitschrift für Gastroenterologie, vol.41, pp.165-70, 2003.

K. Lin, F. Wang, M. Wu, B. Jiang, W. Kao et al., Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: a systematic review and meta-analysis, Diagn Microbiol Infect Dis, vol.80, pp.72-80, 2014.

S. Khedher, N. Fouthaili, A. Maoui, S. Lahiani, M. Salem et al., The diagnostic and prognostic values of C-Reactive Protein and procalcitonin during bacterial infections in decompensated cirrhosis, Gastroenterology Research and Practice, pp.1-6, 2018.

J. Qu, P. Feng, Y. Luo, and X. Lü, Impact of hepatic function on serum procalcitonin for the diagnosis of bacterial infections in patients with chronic liver disease, Medicine, p.2016

I. Elefsiniotis, M. Skounakis, E. Vezali, K. Pantazis, A. Petrocheilou et al.,

, Clinical significance of serum procalcitonin levels in patients with acute or chronic liver disease, Eur J Gastroenterol Hepatol, vol.18, pp.525-555, 2006.

P. Tandon and G. Garcia-tsao, Bacterial Infections, Sepsis, and Multiorgan Failure in Cirrhosis, Semin Liver Dis, vol.28, pp.26-42, 2008.

M. Cazzaniga, E. Dionigi, G. Gobbo, A. Fioretti, V. Monti et al., The systemic inflammatory response syndrome in cirrhotic patients: Relationship with their in-hospital outcome, J Hepatol, vol.51, pp.475-82, 2009.

S. K. Taneja and R. K. Dhiman, Prevention and management of bacterial infections in cirrhosis, Int J Hepatol, p.784540, 2011.

J. Fernández, P. Tandon, J. Mensa, and G. Garcia-tsao, Antibiotic prophylaxis in cirrhosis: Good and bad, Hepatology, vol.63, pp.2019-2050, 2016.

R. H. Shayto, A. Mrad, R. Sharara, and A. I. , Use of rifaximin in gastrointestinal and liver diseases, World J Gastroenterol, vol.22, pp.6638-51, 2016.

R. Ennaifer, E. Nour, M. Cheikh, H. Romdhane, H. Nejma et al., Rifaximin: a potential alternative to prevent bacterial infection in cirrhotic patient?, J Afr Hepato-Gastroenterol, vol.9, pp.122-128, 2015.

M. Mariani, V. Zuccaro, S. Patruno, L. Scudeller, P. Sacchi et al., The impact of rifaximin in the prevention of bacterial infections in cirrhosis, Eur Rev Med Pharmacol Sci, vol.21, pp.1151-1158, 2017.

P. Lutz, M. Parcina, I. Bekeredjian-ding, H. D. Nischalke, J. Nattermann et al.,

, Impact of Rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites, PLoS ONE, vol.9, 2014.

P. Angeli, M. Bernardi, C. Villanueva, C. Francoz, R. P. Mookerjee et al.,

, Clinical Practice Guidelines for the management of patients with decompensated cirrhosis, J Hepatol, vol.69, pp.406-60, 2018.

D. Martino, V. Weil, D. Cervoni, J. Thevenot, and T. , New prognostic markers in liver cirrhosis, World J Hepatol, vol.7, pp.1244-50, 2015.

P. Fischer, C. Grigoras, A. Bugariu, O. Nicoara-farcau, H. Stefanescu et al., Are presepsin and resistin better markers for bacterial infection in patients with decompensated liver cirrhosis?, Dig Liver Dis, p.0, 2019.

H. Wang, Y. Li, F. Zhang, N. Yang, N. Xie et al., Combination of PCT, sNFI and dCHC for the diagnosis of ascites infection in cirrhotic patients, BMC Infect Dis, vol.18, 2018.

C. Chan and J. Levitsky, Infection and alcoholic liver disease, Clin Liver Dis, vol.20, pp.595-606, 2016.

G. Szabo and B. Saha, Alcohol's effect on host defense, Alcohol Res Curr Rev, vol.37, pp.159-70, 2015.

A. R. Levine, M. Tran, J. Shepherd, and E. Naut, Utility of initial procalcitonin values to predict urinary tract infection, Am J Emerg Med, vol.36, 1993.